Dan S. GombosJohn HungerfordDavid H. AbramsonJudith KingstonGuillermo ChantadaIra J. DunkelCelia B.G. AntoneliMark GreenwaldBarret G. HaikCarlos A. LealAurora Medina-SansonAmy C. ScheflerGavivann VeerakulRegina WielandNorbert BornfeldMathew W. WilsonChristopher Bing On YuUniversity of Texas MD Anderson Cancer CenterBarts and The London NHS TrustMoorfields Eye Hospital NHS Foundation TrustMemorial Sloan-Kettering Cancer CenterHospital JP GarrhanHospital Sao PauloUniversity of ChicagoUniversity of Tennessee Health Science CenterInstituto Nacional de PediatriaHospital Infantil de Mexico Federico GomezUniversity of Miami Leonard M. Miller School of MedicineMahidol UniversityUniversitat Duisburg-EssenChinese University of Hong Kong2018-08-242018-08-242007-07-01Ophthalmology. Vol.114, No.7 (2007), 1378-1383016164202-s2.0-34347342867https://repository.li.mahidol.ac.th/handle/20.500.14594/24841Purpose: To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB). Design: Retrospective observational cases series. Participants: Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center. Methods: Physician survey, retrospective database review, and literature search. Main Outcome Measures: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead). Results: Fifteen patients with sAML were identified; 13 occurred in childhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79 %) had received chemotherapy with a topoisomerase II inhibitor, 8 (43%) had received chemotherapy with an epipodophyllotoxin. Ten children died of their leukemia. Conclusions: Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort. © 2007 American Academy of Ophthalmology.Mahidol UniversityMedicineArticleSCOPUS10.1016/j.ophtha.2007.03.074